ICG-Maleimide in photodynamic therapy Neurosurgery CAS 2143933-81-5 ICG-Maleimide

The application of ICG-MAL in photodynamic therapy is mainly as a photosensitizer, which destroys tumor cells by activating ICG-MAL to produce a thermal effect or generating activated state oxygen. Photodynamic therapy is a combination treatment method using photosensitizers and light sources that selectively kills tumor cells while preserving normal tissues. The following are applications of ICG-MAL in photodynamic therapy and corresponding examples:

1. Thermal effect therapy: ICG-MAL can produce thermal effect by absorbing light energy and destroy tumor cells. In the treatment, ICG-MAL is injected into the patient's vein and collects in the tumor tissue. The surgeon then uses a light source to irradiate the tumor area, activating ICG-MAL to produce a thermal effect that causes the tumor cells to be destroyed by heat. For example, ICG-MAL can bind to specific receptors on the surface of tumor cells, destroying the tumor cells through the thermal effect, such as the HER2 receptor in breast cancer cells.

2. Activated state oxygen therapy: ICG-MAL can also destroy tumor cells by activating state oxygen. In the treatment, ICG-MAL is injected into the patient's body and collects in the tumor tissue. The surgeon then irradiates the tumor area with a light source of a specific wavelength, which activates ICG-MAL to produce activated state oxygen, thereby destroying the tumor cells. For example, ICG-MAL can bind to specific molecules in tumor cells and destroy the tumor cells through the generation of activated state oxygen, such as the PD-L1 molecule in lung cancer cells.

3. Photodynamic therapy monitoring: ICG-MAL can also be used for treatment monitoring after photodynamic therapy. After treatment, the surgeon can use a fluorescence microscope or other fluorescence imaging equipment to observe the fluorescence signal of ICG-MAL. If the fluorescent signal weakens or disappears, it indicates that the photodynamic therapy has produced damage to the tumor cells. This can be used to assess the effectiveness of the treatment and to monitor tumor progression. For example, ICG-MAL can bind to a specific signaling pathway in tumor cells, and changes in this signaling pathway can be monitored by fluorescence imaging to assess the effect of photodynamic therapy.

In summary, ICG-MAL acts as a photosensitizer in photodynamic therapy and can destroy tumor cells by activation to produce thermal effects or activated state oxygen. It can bind to specific molecules on the surface of tumor cells and destroy tumor cells by photodynamic therapy, such as HER2 receptor in breast cancer cells and PD-L1 molecule in lung cancer cells.